Pricing Log in Create free account

Genmab A/S Sponsored ADR (GMAB) vs Royalty Pharma PLC (RPRX)

Genmab A/S Sponsored ADR and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $38.0B against $33.8B — 1.1× the size. Royalty Pharma PLC trades at the lower P/E: 36.1× against 44.9×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against 10.0%. Royalty Pharma PLC has the higher net margin (32.0% vs 19.1%) and the lower return on invested capital (5.28% vs 6.99%). Across the 21 metrics below, Royalty Pharma PLC leads on 11 and Genmab A/S Sponsored ADR on 10.

Valuation

Metric GMAB RPRX Biotechnology median
P/E 44.88 36.12 12.43
P/S 8.46 11.79 10.53
P/B 5.87 3.06 2.24
Price to free cash flow n/m 22.82 22.59
EV/EBITDA 33.10 24.57 0.69
EV/Sales 9.34 14.99 9.92
Earnings yield 2.23% 2.77% (34.94%)
Free cash flow yield (18.15%) 4.38% (23.17%)

Profitability

Metric GMAB RPRX Biotechnology median
Gross margin 93.03% 100.00% 68.94%
Operating margin 25.95% 59.61% 0.00%
Net margin 19.08% 32.02% 0.00%
Free cash flow margin (153.64%) 51.66% 0.00%
Return on equity 14.00% 8.42% (54.09%)
Return on assets 8.30% 4.26% (46.84%)
Return on invested capital 6.99% 5.28% 0.00%

Growth

Metric GMAB RPRX Biotechnology median
Revenue growth (TTM) 22.26% 10.01% 6.72%
EPS growth (last fiscal year) (12.50%) (6.81%) 29.36%
Revenue growth, 5-year CAGR 19.15% 2.30% 9.96%
Net income growth, 5-year CAGR 5.73% (4.59%) 0.00%

Health

Metric GMAB RPRX Biotechnology median
Debt to equity 0.86 0.92 0.00
Current ratio 2.46 2.80 5.00
Net debt to EBITDA 3.13 5.22 1.01

Dividend

Metric GMAB RPRX Biotechnology median
Dividend yield — 1.73% 0.40%
Payout ratio — 0.66 —

Size

Metric GMAB RPRX Biotechnology median
Market cap 33.76b 38.00b 177.44m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack